CDKN2A and neoplasm: We found that co‐deletion of IFN‐I and CDKN2A or CDKN2B was associated with poor clinical outcomes and downregulated expression of genes related to inflammatory response, adaptive immune response, and JAK‐STAT signaling in the tumor microenvironment.